March 23 (Reuters) - EVELO BIOSCIENCES INC :
   * EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE STRATEGIC COLLABORATION
   * COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST, TURKEY, AND AFRICA
   * THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL FOR EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS HOSPITALIZED WITH COVID-19
   * TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE DEVELOPING WORLD
   * UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN UPFRONT PAYMENT AND EQUITY INVESTMENT
   * EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURING OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN THE AGREED-UPON REGIONS
   * EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A 50:50

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)